216 related articles for article (PubMed ID: 28411252)
1. Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.
Stevens WBC; Mendeville M; Redd R; Clear AJ; Bladergroen R; Calaminici M; Rosenwald A; Hoster E; Hiddemann W; Gaulard P; Xerri L; Salles G; Klapper W; Pfreundschuh M; Jack A; Gascoyne RD; Natkunam Y; Advani R; Kimby E; Sander B; Sehn LH; Hagenbeek A; Raemaekers J; Gribben J; Kersten MJ; Ylstra B; Weller E; de Jong D
Haematologica; 2017 Aug; 102(8):1413-1423. PubMed ID: 28411252
[TBL] [Abstract][Full Text] [Related]
2. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association.
Kridel R; Xerri L; Gelas-Dore B; Tan K; Feugier P; Vawda A; Canioni D; Farinha P; Boussetta S; Moccia AA; Brice P; Chavez EA; Kyle AH; Scott DW; Sanders AD; Fabiani B; Slack GW; Minchinton AI; Haioun C; Connors JM; Sehn LH; Steidl C; Gascoyne RD; Salles G
Clin Cancer Res; 2015 Aug; 21(15):3428-35. PubMed ID: 25869385
[TBL] [Abstract][Full Text] [Related]
4. FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.
Mottok A; Jurinovic V; Farinha P; Rosenwald A; Leich E; Ott G; Horn H; Klapper W; Boesl M; Hiddemann W; Steidl C; Connors JM; Sehn LH; Gascoyne RD; Hoster E; Weigert O; Kridel R
Blood; 2018 Jan; 131(2):226-235. PubMed ID: 29122756
[TBL] [Abstract][Full Text] [Related]
5. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
Rossi D; Bruscaggin A; La Cava P; Galimberti S; Ciabatti E; Luminari S; Rigacci L; Tucci A; Pulsoni A; Bertoldero G; Vallisa D; Rusconi C; Spina M; Arcaini L; Angrilli F; Stelitano C; Merli F; Gaidano G; Federico M; Palumbo GA
Haematologica; 2015 Apr; 100(4):517-24. PubMed ID: 25596266
[TBL] [Abstract][Full Text] [Related]
6. Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Watanabe R; Tomita N; Kishimoto K; Koyama S; Ogusa E; Ishii Y; Miyashita K; Matsuura S; Fujisawa S; Hattori Y; Takasaki H; Fujita A; Ohshima R; Kuwabara H; Hashimoto C; Fujimaki K; Sakai R; Ishigatsubo Y
Leuk Res; 2013 Oct; 37(10):1208-12. PubMed ID: 23927994
[TBL] [Abstract][Full Text] [Related]
7. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Nam SJ; Go H; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Leuk Lymphoma; 2014 Nov; 55(11):2466-76. PubMed ID: 24397616
[TBL] [Abstract][Full Text] [Related]
8. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP.
Taskinen M; Karjalainen-Lindsberg ML; Leppä S
Blood; 2008 May; 111(9):4664-7. PubMed ID: 18309035
[TBL] [Abstract][Full Text] [Related]
9. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K;
Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034
[TBL] [Abstract][Full Text] [Related]
10. High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma.
Marchesi F; Cirillo M; Bianchi A; Gately M; Olimpieri OM; Cerchiara E; Renzi D; Micera A; Balzamino BO; Bonini S; Onetti Muda A; Avvisati G
Hematol Oncol; 2015 Jun; 33(2):110-2. PubMed ID: 24711044
[No Abstract] [Full Text] [Related]
11. Follicular lymphoma: 2012 update on diagnosis and management.
Freedman A
Am J Hematol; 2012 Oct; 87(10):988-95. PubMed ID: 23001911
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
Luminari S; Ferrari A; Manni M; Dondi A; Chiarenza A; Merli F; Rusconi C; Tarantino V; Tucci A; Vitolo U; Kovalchuk S; Angelucci E; Pulsoni A; Arcaini L; Angrilli F; Gaidano G; Stelitano C; Bertoldero G; Cascavilla N; Salvi F; Ferreri AJM; Vallisa D; Marcheselli L; Federico M
J Clin Oncol; 2018 Mar; 36(7):689-696. PubMed ID: 29095677
[TBL] [Abstract][Full Text] [Related]
13. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Tilly H; Morschhauser F; Casasnovas O; Molina TJ; Feugier P; Gouill SL; Haioun C; Tournilhac O; Bouabdallah R; Gabarre J; Lamy T; Cabeçadas J; Becker S; Jardin F; Mounier N; Salles G;
Lancet Haematol; 2018 Sep; 5(9):e403-e410. PubMed ID: 30172345
[TBL] [Abstract][Full Text] [Related]
15. [ALC/AMC Value and Prognosis in Patients with Primary Follicular Lymphoma Treated with R-CHOP Chemotherapy].
Cui Y; Shi P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):177-181. PubMed ID: 29397839
[TBL] [Abstract][Full Text] [Related]
16. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.
Casulo C; Byrtek M; Dawson KL; Zhou X; Farber CM; Flowers CR; Hainsworth JD; Maurer MJ; Cerhan JR; Link BK; Zelenetz AD; Friedberg JW
J Clin Oncol; 2015 Aug; 33(23):2516-22. PubMed ID: 26124482
[TBL] [Abstract][Full Text] [Related]
17. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS.
Dupuis J; Berriolo-Riedinger A; Julian A; Brice P; Tychyj-Pinel C; Tilly H; Mounier N; Gallamini A; Feugier P; Soubeyran P; Colombat P; Laurent G; Berenger N; Casasnovas RO; Vera P; Paone G; Xerri L; Salles G; Haioun C; Meignan M
J Clin Oncol; 2012 Dec; 30(35):4317-22. PubMed ID: 23109699
[TBL] [Abstract][Full Text] [Related]
18. EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.
Martínez-Laperche C; Sanz-Villanueva L; Díaz Crespo FJ; Muñiz P; Martín Rojas R; Carbonell D; Chicano M; Suárez-González J; Menárguez J; Kwon M; Diez Martín JL; Buño I; Bastos Oreiro M
BMC Cancer; 2022 Sep; 22(1):982. PubMed ID: 36104682
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
[TBL] [Abstract][Full Text] [Related]
20. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.
Procházka V; Papajík T; Faber E; Raida L; Kapitáňová Z; Langová K; Prouzová Z; Jarošová M; Indrák K
Leuk Lymphoma; 2014 Jul; 55(7):1584-90. PubMed ID: 24180329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
